Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study

INTRODUCTION: Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), part of the B-cell and Fc receptor signaling pathways. This study evaluated spebrutinib pharmacology and mechanism of action over a 4-week treatment period in patients...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatol Ther
Main Authors: Schafer, Peter H., Kivitz, Alan J., Ma, Jianglin, Korish, Shimon, Sutherland, Donna, Li, Li, Azaryan, Ada, Kosek, Jolanta, Adams, Mary, Capone, Lori, Hur, Eun Mi, Hough, Douglas R., Ringheim, Garth E.
Format: Artigo
Language:Inglês
Published: Springer Healthcare 2019
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7021855/
https://ncbi.nlm.nih.gov/pubmed/31721017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-019-00182-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items